The identification of the executive director of Linghang Medical Biotechnology is exposed: Two founders of Conflux hold concurrent positions.

According to Gate News bot, the latest public information shows that Long Fan and Wu Ming, the two founders of Conflux, also serve as executive directors of the Hong Kong-listed company Leading Pharmaceutical Biotechnology.

Navi Pharmaceutical Biotechnology currently has a total market value of approximately HKD 371 million (equivalent to USD 47.26 million). Meanwhile, the total market value of Conflux (CFX) token has reached USD 393 million, ranking 138th in the cryptocurrency market capitalization leaderboard.

Earlier reports indicated that Pioneer Pharma Biotechnology (00399) announced that the company will sign a memorandum of understanding with Northwestern Foundation (the seller) and Conflux on June 30, 2025, with the intention of acquiring all the shares of the target company. This potential acquisition aims to assist the company in entering the digital innovation field, which will not only diversify the group’s business but is also expected to bring new profit growth points for the group.

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Share
Comment
0/400
No comments
Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate app
Community
English
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)